What analyst predict for Erytech Pharma S.A NASDAQ:ERYP?
Erytech Pharma S.A NASDAQ:ERYP headquartered in France is reporting their earnings on 09/11/2018 before the bell. Street forecast for the quarter ending March 2018 is $-0.5.
According to stock market daily analyst this is Lower then same time previous year. Erytech Pharma S.A, reported EPS for the same quarter last year was $-0.19.
About Erytech Pharma S.A NASDAQ:ERYP
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.
The Company’s lead product, eryaspase, also known under the trade name GRASPA consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells.
|% Change from 52 Week Low|
|% Change from 52 Week High|